The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

OBJECTIVE: To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Headache
Glavni autori: Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Research Submissions
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7590156/
https://ncbi.nlm.nih.gov/pubmed/32851644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13929
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items